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Abstract Glycolytic pyruvate kinase isoenzyme type M2
(M2-PK) plays a key role in tumor metabolism and energy
production. Vascular endothelial growth factor (VEGF) is
critical in regulating angiogenesis which is an essential
process required for tumor growth and metastasis. These two
genes may function in accordance with tumor development.
The purpose of this study was to investigate the relationship
between the expression of M2-PK and VEGF, and their
association with clinicopathological features in patients with
advanced gastric cancer. Expression of M2-PK and VEGF
were examined in 142 cases of paraffin-embedded tissue
blocks from patients with advanced gastric cancer. M2-PK
expression was found to strongly correlate with that of
VEGF (r = 0.718). In addition, expression of M2-PK and
VEGF correlates with tumor size (p = 0.0001, and
p = 0.0017, respectively), depth of invasion (p = 0.0024,
and p = 0.0261, respectively), and lymph node metastasis
(p = 0.036, and p = 0.028, respectively). The high
expression levels of M2-PK and VEGF may indicate poor
prognosis in patients with advanced gastric cancer.
Keywords M2 pyruvate kinase isoenzyme  Vascular
endothelial growth factor  Advanced gastric cancer
Introduction
Gastric cancer is a significant global health burden.
Approximately 934,000 new cases of gastric cancer are
diagnosed annually (representing 8.6 % of all new cancer
cases) [1]. Nearly two-thirds of all gastric cancer cases are
found in developing countries, with 42 % in China alone
[2]. Gastric cancer remains an aggressive disease with a
high mortality rate. Despite a marked decrease in the
mortality of gastric cancer in most areas of the world [3, 4],
this malignancy remains the second leading cause of can-
cer-related death worldwide. It has a 5-year survival rate of
*20 % [5–7]. Post-operative recurrence is a major prob-
lem, and is often the ultimate cause of death. The reported
major factors determining the prognosis include depth of
tumor invasion, lymph node metastasis, and tumor size [8].
Tumor angiogenesis plays a critical role in tumor growth
and metastasis [9–11]. Any increase in a tumor mass must
be preceded by an increase in the microvasculature to
deliver nutrients and oxygen to the tumor and remove
products of tumor metabolism. Without new blood vessels,
most tumors would never grow beyond 1–2 mm in diam-
eter and would remain localized to the primary site [10].
Tumor cells generally display high rates of aerobic gly-
colysis [11]. The glycolytic pyruvate kinase isoenzyme type
M2 (M2-PK) plays a key role by channeling glucose carbons
either into synthetic processes or toward glycolytic energy
production. In tumor cells, M2-PK is predominantly present
as a dimeric form known as tumor M2-PK. Dimerization M2-
PK appears to be caused by direct interaction between M2-PK
and certain oncoproteins. This is thought to be a regulatory
mechanism which allows tumor cells to survive in environ-
ments with varying oxygen and nutrient supplies [12].
In this study, we aimed to examine the expression of
M2-PK and VEGF and determine whether these biological
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parameters could be used to predict the outcome of patients
with advanced gastric cancer.
Materials and Methods
Patients and Tumor Specimens
We collected 142 paraffin-embedded tissue blocks from
patients with advanced gastric cancer who underwent cura-
tive surgery at Lanzhou University Second Hospital between
January 2005 and December 2007. None of these patients
received chemotherapy or radiation therapy before surgery.
However, all patients had received six cycles of standard
post-operative adjuvant chemotherapy with 5-fluorouracil
(5-FU) and leucovorin (LV) plus oxaliplatin. Patients were
regularly followed-up at the outpatient clinic after surgery
and the survival data as of January 2011 were obtained
through hospital records. The median follow-up duration
was 32 months (range: 1–66 months). The three-year sur-
vival rate is 35.9 %. Forty-one patients died of cancer
recurrence within one year, and 75 patients died within two
year of surgery. Fifty-one and 31 patients were disease free at
three and five years post-surgery, respectively.
Clinicopathological Data
Age at surgery, gender, tumor factor, tumor invasion,
tumor size, lymph node metastasis, tumor stage, Borrmann
type, and histologic grading were recorded in the survivors.
Stage classification was according to the Union for Inter-
national Cancer Control (UICC) system [13].
Immunohistochemical Staining
Paraffin-embedded tissues were cut into 4 lm sections,
deparaffinized with xylene and washed with PBS. After
blocking with 1 % goat serum in PBS for 15 min, slides were
incubated with a polyclonal rabbit anti-VEGF (Santa Cruz,
CA, USA) (dilution: 1:100), or a polyclonal rabbit anti-M2-
PK (ScheBo Biotech, Giessen, Germany) (dilution: 1:100) for
45 min at room temperature. The anti-M2-PK only recognizes
the dimeric form of M2-PK, which is the predominant form of
M2-PK in tumor tissues [14]. The slides were washed with
PBS and incubated with the appropriate biotinylated second-
ary antibodies. The slides were then washed and incubated
with streptavidin–peroxidase (DAKO, Shanghai, China)
according to the manufacturer’s instructions, followed by
incubation with 3,30-diaminobenzidine (DAB) (DAKO,
Shanghai, China) and counterstained with hematoxylin. The
stained slides were examined by two pathologists who were
blinded to the clinical information and the nature of speci-
mens. The immunoreactivity was scored as shown in Table 1.
Statistical Analysis
The statistical analysis was performed using SPSS (version
12.0). Correlation of M2-PK and VEGF staining with clin-
icopathological parameters was analyzed using Chi square
test. Correlation between M2-PK and VEGF was determined
by the Pearson Correlation Coefficient analysis. Kaplan–
Meier analysis was used to assess the patient survival. A
p value of\0.05 was considered statistically significant.
Results
Clinicopathological Findings
As summarized in Table 2, gastric cancer is more common in
men than in women. Most gastric cancer patients are younger
than 60 years when diagnosed. Most of these gastric cancer
patients (89/142, 62.7 %) had T2 tumors, followed by T3
(35/142, 24.6 %), and T4 tumors (11/142, 7.7 %), whereas
only a small number of patients were in T1 phase (7/142,
5 %). When the tumors were stratified according to the
extent of invasion into early (T1) and late (T2–T4) stages, it
was revealed that in the vast majority of patients (135/142,
95 %), the tumors had reached late stages, with most having
large tumors (defined as[3 cm, 96/142, 67.6 %) and lymph
node metastasis (125/142, 88 %). Using either UICC or
Borrmann staging system, it was revealed that the majority of
patients were in stages II and III (75.4 and 88.7 %, respec-
tively). Although these tumors were diagnosed at relatively
late stages, they generally showed either moderate (84/142,
59.2 %) or well (31/142, 21.8 %) differentiation, with only
19 % were poorly differentiated.
Immunohistochemical Features
Positive staining for M2-PK and VEGF was observed in
most cases of gastric cancer tissues (93/142, 65.49 %, and
87/142, 61.27 %, respectively). Both M2-PK and VEGF
Table 1 The scoring system for immunohistochemistry
Staining Score
No 0
Positive in \5 % of tumor cells 1
Positive in 5–25 % of tumor cells 2
Positive in [25 % of tumor cells 3
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are mainly expressed in the cytoplasm or on the membrane
of the cancer cells. Table 3 summarizes the detailed
immunohistochemical staining data and their correlation
with the clinicopathological features. Typical immuno-
staining results were shown in Fig. 1.
Correlation Between the Expression of M2-PK
and VEGF, and the Clinicopathological Features
M2-PK and VEGF were significantly correlated with tumor
size (p = 0.0001 and p = 0.0017, respectively), depth of
invasion (p = 0.0024 and p = 0.0261, respectively), and
lymph node metastasis (p = 0.036 and p = 0.028, respec-
tively). The expression of both proteins did not correlate with
gender, differentiation status, and tumor staging either by
Borrmann classification or UICC system. These data were
summarized in Table 3.
Correlation Between the Expression of M2-PK
and VEGF, and Patient Survival
The prognostic value of M2-PK and VEGF on patients with
advanced gastric cancer was evaluated and compared
between patients with high and low expressions of both
proteins. Using a Kaplan–Meier curve, we found that low
M2-PK and VEGF expression in tumor tissue was an
independent predictor for poor prognosis in patients with
Table 2 Clinicopathological findings in 142 patients with gastric
cancer
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Table 3 Expression of M2PK and VEGF, and their correlation with
clinicopathological features
Variables M2PK scores p value VEGF scores p value
0–1 2–3 0–1 2–3
Gender
Male 19 79 14 84
Female 13 32 0.16 12 33 0.62
Age
\60 21 59 15 65
C60 10 52 0.85 11 51 0.06
Tumor size
\3 cm 13 33 24 22
3–5 cm 15 54 13 56
[5 cm 2 26 0.0001* 3 26 0.0017*
Tumor invasion
T1 7 0 11 14
T2 24 66 28 42
T3 12 20 12 23
T4 4 8 0.0024* 3 9 0.0261*
UICC stage
I 7 15 6 12
II 13 27 18 35
III 19 38 19 38
IV 6 11 0.068 5 7 0.122
Lymph node metastasis
No 7 11 6 12
Yes 44 81 0.036* 38 86 0.028*
Histologic grade
Well 2 28 4 26
Moderate 22 64 17 69
Poor 6 20 0.909 3 23 0.123
Borrmann
I 1 4 0 5
II 15 47 11 51
III 13 51 13 51
IV 2 9 0.579 1 0 0.926
* p \ 0.05 was considered statistically significant
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advanced gastric cancer. The five-year overall survival rate
in patients expressing lower levels of M2-PK and VEGF
was significantly better than those expressing higher levels
of both proteins (p \ 0.01) (Fig. 2a, b, respectively).
Univariate and Multivariate Analysis of Prognosis
Variables
To identify the variables of potential prognostic signifi-
cance in patients with advanced gastric cancer, univariate
and multivariate analyses were carried out using the Cox
proportional hazard model to compare the impact of the
expression levels of M2-PK and VEGF and other clinical
pathological parameters on the prognosis. It has been
revealed that M2-PK and VEGF expression, tumor size and
UICC stage were significant prognostic factors in these
patients (Table 4).
Correlation Analysis Between M2-PK and VEGF
Expression
There is a significant correlation between M2-PK and
VEGF expression in advanced gastric cancer (r = 0.718,
p \ 0.01).
Discussion
Recent studies have indicated that M2-PK and VEGF
expression may be prognostic factors in colorectal cancer
[15, 16]. In this study, we focused on the possible prog-
nostic value of M2-PK and VEGF in patients with
advanced gastric cancer.
Growth of tumor cells requires constant energy supply
through neovascularization (angiogenesis) [17]. Tumor
cells are capable of utilizing glucose for energy and meta-
bolic substrate production even under anaerobic conditions.
VEGF, the most important regulator of the angiogenesis,
promotes the recruitment and proliferation of endothelial
cells and their precursors within the tumor, and thus plays a
critical role in angiogenesis during tumor development [18,
19]. High VEGF expression is reported in several malig-
nancies [20], and VEGF expression has been correlated
with poor prognosis of breast cancer [21] and ovarian
cancer [22]. High level of VEGF expression has been
observed in gastric carcinomas [23]. Expression of VEGF
has been shown to correlate positively with microvessel
count and metastasis [24]. In gastric cancer, VEGF (now
termed VEGF-A) is one of the strongest promoters of
angiogenesis [25].
Fig. 1 Expression of M2-PK
(a, 9200) and VEGF (b, 9200)
in primary gastric cancer tissues
and gastric cancer metastasized
to lymph nodes (c and d,
respectively, all 9100)
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In our analysis, patients with the higher VEGF expres-
sion had significantly poorer prognosis than those with
lower expression levels. The level of VEGF correlated with
TNM stages of advanced gastric cancer. This result is
consistent with the reported data [26]. We also observed a
reduced disease-free and metastases-free survival in
patients with VEGF-positive tumors. This finding is again
consistent with what has previously been reported that
positive VEGF is an indicator of poor survival and distant
metastasis [27].
In tumor cells, increased aerobic glycolysis is one of the
most common metabolic phenomenons. Tumor cells in
particular express the pyruvate kinase isoenzyme type M2.
The enzyme pyruvate kinase (PK) plays a central role in
aerobic glycolysis, a metabolic process that is increased in
tumor cells [28]. The M2-PK, which can switch between a
highly active tetrameric form and an inactive dimeric form,
is an important metabolic sensor to adapt tumor metabolism
in nutrient and oxygen supply conditions. In tumor cells,
generally the dimeric form of M2-PK is dominant and is
released into the blood stream [29], and is therefore termed
tumor M2-PK [30]. Tumor metastases are always charac-
terized by homogeneous expression of large amounts of
tumor M2-PK [31–33]. Elevated serum concentrations of
M2-PK have been found to correlate with poor prognosis in
patients with pancreaticobiliary and duodenal cancer [34].
Only limited data are available on tumor M2-PK in gastric
cancer. The tumor M2-PK has been shown to be present not
Fig. 2 Patients expressing lower levels of M2-PK (a) and VEGF
(b) show significantly better 5-year overall survival compared to those
with higher expression levels of both protein (p \ 0.01)
Table 4 The mean survival time of the patients in different groups of
various prognostic factors
Risk factors Mean ± SEMa p valueb
Gender
Female 30.90 ± 22.55 NS
Male 29.40 ± 21.47
Age (years)
\60 33.95 ± 22.73 NS
C60 26.60 ± 19.31
M2PK expression
0–1 48.90 ± 18.14 \0.0001
2–3 24.55 ± 19.63
VEGF expression
0–1 51.28 ± 17.16 \0.01
2–3 35.29 ± 19.84
Tumor size
\3 cm 33.24 ± 21.19
3–5 cm 31.33 ± 22.35 NS
C5 cm 20.82 ± 19.19 0.017
Tumor invasion
T1–T2 32.72 ± 22.80
T3–T4 26.83 ± 17.19 0.061
Lymph node metastasis
N0–N1 31.47 ± 18.63
N2 or N3 27.45 ± 22.25 NS
UICC stage
I–II 43.17 ± 21.00
III–IV 24.11 ± 22.57 \0.01
Borrmann
I–II 35.63 ± 21.27
III–IV 27.72 ± 20.98 0.095
Histologic grade
Well 36.17 ± 19.00
Moderate 30.42 ± 22.38
Poor 34.22 ± 21.90 NS
NS not significant
a The mean survival time, in months, was calculated by the Kaplan–
Meier estimates of survival functions
b The p values were based on the log rank test. p \ 0.05 was con-
sidered statistically significant
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only in plasma, but also in feces, indicating that M2-PK
may serve as a potential marker for screening colorectal and
gastric cancers in high risk individuals [35, 36]. In our
studies, patients with higher level of M2-PK expression had
significantly poorer prognosis than those with lower M2-PK
expression. The level of M2-PK correlated with tumor size
(p = 0.0001), depth of invasion (p = 0.0024) and lymph
node metastasis (p = 0.036 and p = 0.028, respectively).
Expression level of M2-PK and VEGF in gastric cancer
tissues had remarkable correlation (r = 0.718). Such a
close correlation probably reflect the notion that in tumor
tissues, M2-PK and VEGF need to operate together to
provide essential environment to favor tumor growth.
Tumor size is a major determinant for patient survival.
In our series, 96 (67.6 %) of patients had tumors[3 cm in
size, 137 (95 %) of patients had T2–T4 tumors, 125 (88 %)
of patients had lymph node metastasis, and in 77 (54 %)
patients tumors were at stages III–IV. The fact that patients
were generally diagnosed at advanced stages is partially
due to the poor social-economic status and a lack of
essential public health knowledge in the patient population.
In these patients with advanced gastric cancer, M2-PK and
VEGF expression, tumor size and UICC stage were all
significant independent prognostic factors.
In conclusion, M2-PK and VEGF expression were
positively correlated with the prognosis of advanced gastric
cancer. Further studies are required to confirm the role of
simultaneous analysis of these two proteins as a potential
approach for determining the tumor progression and
prognosis in patients with gastrointestinal malignancies.
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